Seattle Genetics CEO Clay Siegall’s WordPress blog has a story about AJ McCarron, a veteran NFL quarterback. He played for the Cincinnati Bengals but is now an unrestricted free agent. It appears that the New York Jets are interested in signing him to a contract. Other teams that are also interested in him could be the Cardinals, Jaguars, and Broncos.
Another article on his blog is about the Miami Dolphins and their Wide Receiver Jarvis Landry. The Dolphins are looking to sign him to a long-term deal before the start of free agency. He said he wants to continue playing for the Dolphins and wasn’t troubled that they didn’t sign him to a long-term contract before the start of last season. He’s 25 years old and is considered to be one of the best wide receivers in the league.
Clay Siegall’s leadership is credited with Seattle Genetics success as a research and development firm concentrated on developing cures for cancer. Their 2017 earnings figures were released in early 2018 and he and his team earned $482.3 million in revenue for the year, beating market expectations. Clay Siegall said that their first cancer drug, Adcetris, is growing in commercial sales and in 2017 received FDA approval for treatment of a fourth form of cancer. He also said that the phase 3 part of their clinical trial for Echelon-1 also achieved a positive outcome.
Since co-founding this company in 1998, Clay Siegall has developed the company by forming partnerships with other firms in the industry, such as Takeda. As his company matures, though, Clay Siegall says that he feels Seattle Genetics is beginning to not need to form partnerships any longer. He says that one of their most important cancer drugs, Ladiratuzumab vedotin, which treats breast cancer, is fully owned by his company, for example. He plans on handling the launch of this drug in the United States and internationally in-house rather than how he partnered with Takeda to launch Adcetris. In order to help in this effort he opened a new business unit in Europe called SeaGen International GmbH.